Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Cancer cells

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 2204382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved use of buthionine sulfoximine to prevent cisplatin nephrotoxicity in rats

  2004cited by this paper
• Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide

  2004cited by this paper
• Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells

  2004cited by this paper
• In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay

  2004cited by this paper
• Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells.

  1989cited by this paper
• Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines.

  1989cited by this paper
• Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin

  1989cited by this paper
• Metallothionein induction in mouse tissues by cis-dichlorodiammineplatinum(II) and its hydrolysis products.

  1989cited by this paper
• DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.

  1989cited by this paper
• 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.

  1989cited by this paper
• The effect of reduced osmolarity on platinum drug toxicity.

  1989cited by this paper
• Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives.

  1989cited by this paper
• Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell line.

  1989cited by this paper
• Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II)

  1989cited by this paper
• Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia.

  1989cited by this paper
• Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug.

  1989cited by this paper
• Induction of beta-polymerase mRNA by DNA-damaging agents in Chinese hamster ovary cells

  1989cited by this paper
• Molecular basis of cisplatin resistance in human carcinomas: model systems and patients.

  1989cited by this paper
• Resistance to platinum compounds: mechanisms and beyond.

  1989cited by this paper
• Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line.

  1989cited by this paper
• Enhancement of the antiproliferative effect of cis‐diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C

  1988cited by this paper
• Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks.

  1988cited by this paper
• Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

  1988cited by this paper
• Interaction of cis-diamminedichloroplatinum(II) with sensitive and resistant L1210 cell lines. Drug binding to nuclei and DNA.

  1988cited by this paper
• LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN

  1988cited by this paper
• The Mechanism of Acquired Resistance to Cisplatin by a Human Ovarian Cancer Cell Line

  1988cited by this paper
• Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.

  1988cited by this paper
• cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

  1988cited by this paper
• Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

  1988cited by this paper
• Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

  1988cited by this paper
• Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA.

  1988cited by this paper
• Enhancement of cis‐diamminedichloroplatinum and mitomycin c‐induced sister chromatid exchanges by dibutyryl cyclic amp in a human salivary gland adenocarcinoma cell line in culture

  1988cited by this paper
• Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.

  1988cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

  1988cited by this paper
• Molecular cloning and biological characterization of a human gene, ERCC2, that corrects the nucleotide excision repair defect in CHO UV5 cells

  1988cited by this paper
• Enhanced DNA repair and resistance to cisplatin in human ovarian cancer.

  1988cited by this paper
• Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.

  1988cited by this paper
• Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes.

  1988cited by this paper
• cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.

  1988cited by this paper
• Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line.

  1988cited by this paper
• Biological and biochemical consequences of the human ERCC-1 repair gene after transfection into a repair-deficient CHO cell line.

  1987cited by this paper
• Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II).

  1987cited by this paper
• Cyclic AMP levels of C6 glioma cells treated with cis-dichlorodiammine platinum (cis-DDP).

  1987cited by this paper
• Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.

  1987cited by this paper
• Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).

  1987cited by this paper
• Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes.

  1987cited by this paper
• Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.

  1987cited by this paper
• Decreased cisplatin uptake by resistant L1210 leukemia cells.

  1987cited by this paper
• Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice.

  1987cited by this paper
• Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.

  1987cited by this paper
• Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

  1986cited by this paper
• Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs.

  1986cited by this paper
• Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro.

  1986cited by this paper
• Amino acid membrane transport properties of L1210 cells resistant to cisplatin.

  1986cited by this paper
• Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.

  1986cited by this paper
• Binding of cis-dichlorodiammine platinum(II) to metallothionein in Ehrlich cells.

  1985cited by this paper
• Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

  1985cited by this paper
• Fundamental studies with cisplatin.

  1985cited by this paper
• Drugs five years later. Cisplatin.

  1984cited by this paper
• Interaction of platinum with metallothionein-like ligands in the rat kidney after administration of cis-dichlorodiammine platinum II.

  1984cited by this paper
• In vivo and in vitro binding of platinum to metallothionein.

  1984cited by this paper
• Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay.

  1984cited by this paper
• Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.

  1983cited by this paper
• cis-Platinum: subcellular distribution and binding to cytosolic ligands.

  1983cited by this paper
• Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein.

  1981cited by this paper

• Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells

  2024cites this paper
• Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis

  2024cites this paper
• Recent development of nanotechnology-based approaches for gynecologic cancer therapy

  2024cites this paper
• Ascites in malignant ovarian cancer confer ovarian cancer cells chemoresistance to platinum. Combination treatment with crizotinib and 2-hydroxyestradiol restores platinum sensitivity

  2023cites this paper
• Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells

  2023cites this paper
• MeXpose—A Modular Imaging Pipeline for the Quantitative Assessment of Cellular Metal Bioaccumulation

  2023cites this paper
• Prevention of cisplatin-induced nephrotoxicity by kidney-targeted sirna delivery.

  2022cites this paper
• 2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion

  2022cites this paper
• Towards Imaging Pt Chemoresistance Using Gd(III)‐Pt(II) Theranostic MR Contrast Agents

  2021cites this paper
• In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([189, 191Pt]cisplatin) Emitting Auger Electrons

  2021cites this paper
• UN-RIPED fruit pods of Prosopis cineraria (L.) Druce ameliorates cisplatin theraphy induced partial testicular atrophy in MALE Wistar rats.

  2020cites this paper
• Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer

  2020cites this paper
• Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion

  2020cites this paper
• Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors

  2019cites this paper
• Transformation of follicular lymphoma to double-hit lymphoma during adjuvant chemotherapy for concurrent ovarian carcinoma

  2019cites this paper
• Identification of lncRNA–miRNA–mRNA regulatory network associated with epithelial ovarian cancer cisplatin‐resistant

  2019cites this paper
• Metallothionein: Potential therapeutic target for osteosarcoma

  2019cites this paper
• Quantitative evaluation of the intratumoral distribution of platinum in oxaliplatin‐treated rectal cancer: In situ visualization of platinum via synchrotron radiation X‐ray fluorescence spectrometry

  2019cites this paper
• Platinum drugs, copper transporters and copper chelators

  2018cites this paper
• Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients

  2018cites this paper
• An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer

  2018cites this paper
• N‐acetylcysteine transforms necrosis into apoptosis and affords tailored protection from cisplatin cytotoxicity

  2018cites this paper
• Upregulated microRNA‐193a‐3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells

  2018cites this paper
• The Value of Early Depth of Response in Predicting Long‐Term Outcome in EGFR‐Mutant Lung Cancer

  2018cites this paper
• Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis

  2018cites this paper
• Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis

  2018cites this paper
• Chapter 4 Short-Chain Fatty Acids Are Antineoplastic Agents

  2018cites this paper
• PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non‐small‐cell lung cancer

  2018cites this paper
• New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.

  2017cites this paper
• Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters.

  2017cites this paper
• Development and in vitro characterization of nanoparticles for inner ear drug delivery

  2017influential citation
• Cancer-Specific, Intracellular, Reductive Activation of Anticancer PtIV Prodrugs.

  2017cites this paper
• Effect of cisplatin on the transport activity of PII-type ATPases.

  2017cites this paper
• Chapter 5 Implication of Clear Cell and Mucinous Histology

  2017cites this paper
• Short-Chain Fatty Acids Are Antineoplastic Agents

  2017cites this paper
• Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells

  2017cites this paper
• Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

  2016cites this paper
• Role of copper transporters in platinum resistance.

  2016cites this paper
• Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.

  2016cites this paper
• Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer

  2016cites this paper
• Base-Resolution Analysis of Cisplatin-DNA Adducts at the Genome Scale.

  2016cites this paper
• Chemotherapy Resistance in Lung Cancer.

  2016cites this paper
• A Genome-Wide Knockout Screen to Identify Genes Involved in Acquired Carboplatin Resistance

  2016cites this paper
• Development of Non-Traditional Platinum Anticancer Agents: trans-Platinum Planar Amine Compounds and Polynuclear Platinum Compounds

  2015cites this paper
• Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy

  2015cites this paper
• Coordination compounds in cancer: Past, present and perspectives

  2015cites this paper
• Mixed copper-platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: An ESI-MS study.

  2015cites this paper
• Inauhzin(c) Inactivates c-Myc Independently of p53

  2015cites this paper
• Prediction of Protein-Ligand Binding Sites for Cisplatin and Transplatinbased on Hydrogen Bonds

  2015cites this paper
• Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.

  2015cites this paper
• Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.

  2015cites this paper
• New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants.

  2015cites this paper
• Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.

  2015cites this paper
• Profile of vintafolide ( eC 145 ) and its use in the treatment of platinum-resistant ovarian cancer

  2014cites this paper
• Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.

  2014cites this paper
• Non-specificity and synergy at the binding site of the carboplatin-induced DNA adduct via molecular dynamics simulations of the MutSα–DNA recognition complex

  2014cites this paper
• Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin

  2014cites this paper
• Ruthenium Complexes:-Potential candidate for Anti-Tumour Activity

  2014cites this paper
• Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells

  2014cites this paper
• Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin.

  2014cites this paper
• Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer

  2014cites this paper
• Chemotherapeutic Agents for the Treatment of Hepatocellular Carcinoma: Efficacy and Mode of Action

  2014cites this paper
• The Role of Base Excision Repair and Mismatch Repair Proteins in the Processing of Cisplatin Interstrand Cross-Links

  2014cites this paper
• Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway.

  2014cites this paper
• Destabilization of the MutSα’s protein-protein interface due to binding to the DNA adduct induced by anticancer agent carboplatin via molecular dynamics simulations

  2013cites this paper
• human ovarian cancer cell lines. interstrand cross-links in cisplatin-resistant Increased gene-specific repair of cisplatin

  2013cites this paper
• Action of the anticancer drug cisplatin investigated by molecular simulation

  2013influential citation
• Overcoming cisplatin resistance in chemotherapy by biomineralization.

  2013cites this paper
• Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers

  2013cites this paper
• The study of interactions between antitumor effective heavy metal complexes with biomacromolecules using molecular biophysics methods

  2013cites this paper
• A Re-Evaluation of the Role of hCTR1, the Human High-Affinity Copper Transporter, in Platinum-Drug Entry into Human Cells

  2013cites this paper
• Implication of Clear Cell and Mucinous Histology

  2013cites this paper
• Advances in personalized therapy for lung cancer.

  2013cites this paper
• Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents.

  2013cites this paper
• Citrate inhibition of cisplatin reaction with DNA studied using fluorescently labeled oligonucleotides: implication for selectivity towards guanine.

  2013cites this paper
• Subcellular targets of cisplatin cytotoxicity: an integrated view.

  2012cites this paper
• Transfection of PDCD5 Effect on the Biological Behavior of Tumor Cells and Sensitized Gastric Cancer Cells to Cisplatin-Induced Apoptosis

  2012cites this paper
• Tissue platinum concentration and tumor response in non-small-cell lung cancer.

  2012cites this paper
• Golgi-SNARE GS 28 potentiates cisplatin-induced apoptosis by forming GS 28 – MDM 2 – p 53 complexes and by preventing the ubiquitination and degradation of p 53

  2012cites this paper
• Golgi-SNARE GS28 potentiates cisplatin-induced apoptosis by forming GS28-MDM2-p53 complexes and by preventing the ubiquitination and degradation of p53.

  2012cites this paper
• Target-based selection of flavonoids for neurodegenerative disorders.

  2012cites this paper
• Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro

  2012influential citation
• miR‐34a is downregulated in cis‐diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis

  2012cites this paper
• Structural Determinants of Cisplatin and Transplatin Binding to the Met-Rich Motif of Ctr1: A Computational Spectroscopy Approach.

  2012cites this paper
• Silencing of the SNARE protein NAPA sensitizes cancer cells to cisplatin by inducing ERK1/2 signaling, synoviolin ubiquitination and p53 accumulation.

  2011cites this paper
• Latent membrane protein 1 of Epstein-Barr virus sensitizes cancer cells to cisplatin by enhancing NF-κB p50 homodimer formation and downregulating NAPA expression.

  2011cites this paper
• Univerzita Palackého v Olomouci

  2011cites this paper
• Recently Confirmed Apoptosis-Inducing Lead Compounds Isolated from Marine Sponge of Potential Relevance in Cancer Treatment

  2011cites this paper
• Determination of Pt–DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry

  2011cites this paper
• Copper Transporter 2 Regulates Endocytosis and Controls Tumor Growth and Sensitivity to Cisplatin In Vivo

  2011cites this paper
• High-Mobility Group A1 (HMGA1) Protein Expression Correlates With Cisplatin-Induced Cell Death in Squamous Cell Carcinoma of Skin

  2010cites this paper
• Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis

  2010cites this paper
• Mechanisms of drug resistance in ovarian cancer

  2010cites this paper
• ASNA 1 and cisplatin resistance-studies in C . elegans and in human tumor cells

  2010cites this paper
• Knockdown of NAPA using short-hairpin RNA sensitizes cancer cells to cisplatin: implications to overcome chemoresistance.

  2010cites this paper
• SENSITIVITY OF CISPLATIN-RESISTANT BY LOW-HYPERTHERMIA IN VITRO

  2010cites this paper
• Biomarkers of cell stress and cell death detected by proton high resolution magic angle spinning (¹H HR-MAS) nuclear magnetic resonance (NMR) spectroscopy in a rat glioma cell line.

  2010cites this paper
• Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma

  2010cites this paper
• Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.

  2010cites this paper
• Cancer Therapy: Preclinical Therapeutic Targeting of ATP7B in Ovarian Carcinoma

  2009cites this paper